Table 2.

Factors Associated with Escalation of Discharge Antithrombotic Medication Among Ischemic Stroke Patients with Aspirin Failure^*

Variable	Odds Ratio (95% CI)	P value
Demographics
Age, per one year increase	0.98 (0.98–0.98)	<0.001
Female	0.85 (0.82–0.87)	<0.001
Race/ethnicity
Asian vs. non-Hispanic White	0.92 (0.83–1.02)	0.59
Black vs. non-Hispanic White	0.85 (0.81–0.89)	0.02
Hispanic vs. non-Hispanic White	0.85 (0.79–0.92)	0.12
Other vs. non-Hispanic White	0.88 (0.81–0.96)	0.54
Medical History
Prior Stroke	1.17 (1.13–1.21)	<0.001
Prior TIA	1.20 (1.15–1.25)	<0.001
CAD/Prior MI	1.30 (1.27–1.34)	<0.001
Carotid Stenosis	1.22 (1.15–1.30)	<0.001
Diabetes Mellitus	1.00 (0.97–1.03)	0.83
PVD	1.18 (1.11–1.25)	<0.001
Hypertension	1.07 (1.03–1.11)	<0.001
Smoking	0.97 (0.93–1.01)	0.17
Dyslipidemia	1.11 (1.08–1.15)	<0.001
Heart Failure	1.16 (1.10–1.22)	<0.001
Chronic Kidney Disease	0.93 (0.86–0.98)	0.004
NIHSS
4–9 vs. 0–3	0.89 (0.87–0.92)	<0.001
≥10 vs. 0–3	0.68 (0.65–0.71)	<0.001

^*From no antithrombotics, to single antiplatelet [aspirin or clopidogrel monotherapy], dual antiplatelet therapy of aspirin and clopidogrel [DAPT], and anticoagulant with or without antiplatelet therapy